These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16196043)

  • 1. Estradiol and cognition during androgen deprivation in men with prostate carcinoma.
    Wassersug RJ; Wadhwa D
    Cancer; 2005 Nov; 104(9):2032-3; author reply 2033. PubMed ID: 16196043
    [No Abstract]   [Full Text] [Related]  

  • 2. Estradiol and cognition during androgen deprivation in men with prostate carcinoma.
    Salminen EK; Portin RI; Koskinen AI; Helenius HY; Nurmi MJ
    Cancer; 2005 Apr; 103(7):1381-7. PubMed ID: 15717315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer.
    Alibhai SM; Breunis H; Timilshina N; Marzouk S; Stewart D; Tannock I; Naglie G; Tomlinson G; Fleshner N; Krahn M; Warde P; Canning SD
    J Clin Oncol; 2010 Dec; 28(34):5030-7. PubMed ID: 21041708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone loss and estradiol administration modify memory in men.
    Beer TM; Bland LB; Bussiere JR; Neiss MB; Wersinger EM; Garzotto M; Ryan CW; Janowsky JS
    J Urol; 2006 Jan; 175(1):130-5. PubMed ID: 16406889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate].
    Nedelec C; Ragot S; Irani J; Pires C; Gil R; Doré B
    Prog Urol; 2009 Jan; 19(1):47-53. PubMed ID: 19135642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Arch Intern Med; 2007 Mar; 167(6):612-3. PubMed ID: 17389294
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
    Taxel P; Luthra P; Fall PM; Dauser D
    Aging Male; 2008 Jun; 11(2):71-5. PubMed ID: 18570058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic effects of testosterone deprivation.
    Sprenkle PC; Fisch H
    Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
    Dale W
    J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen deprivation therapy for prostate cancer: effects on hand function.
    Soyupek F; Soyupek S; Perk H; Ozorak A
    Urol Oncol; 2008; 26(2):141-6. PubMed ID: 18312932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estradiol for the mitigation of adverse effects of androgen deprivation therapy.
    Russell N; Cheung A; Grossmann M
    Endocr Relat Cancer; 2017 Aug; 24(8):R297-R313. PubMed ID: 28667081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritis.
    Pope JE; Joneja M; Hong P
    J Rheumatol; 2002 Nov; 29(11):2459-62. PubMed ID: 12415609
    [No Abstract]   [Full Text] [Related]  

  • 14. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk during androgen deprivation therapy for prostate cancer.
    Jones TH
    BMJ; 2011 May; 342():d3105. PubMed ID: 21610041
    [No Abstract]   [Full Text] [Related]  

  • 17. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
    McLeod N; Huynh CC; Rashid P
    Aust Fam Physician; 2006 Apr; 35(4):243-5. PubMed ID: 16642243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Castration of prostate cancer patients and cognition].
    Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
    Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
    [No Abstract]   [Full Text] [Related]  

  • 19. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 20. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.